Clinical Trial: Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07494305) titled 'Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.' on Dec. 26, 2025.

Brief Summary: Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.

Study Start Date: Jan. 23

Study Type: INTERVENTIONAL

Condition: Bipolar I Disorder

Intervention: DRUG: LB-102

N-methyl amisulpride

OTHER: Placebo

Inactive substance that looks identical to the active treatment

Recruitment Status: RECRUITING

Sponsor: ...